Näslund Olivia, Lipatnikova Anna, Dénes Anna, Lindskog Cecilia, Bontell Thomas Olsson, Smits Anja, Jakola Asgeir S, Corell Alba
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Brain Spine. 2022 Dec 27;3:101711. doi: 10.1016/j.bas.2022.101711. eCollection 2023.
Meningiomas account for nearly 40% of intracranial tumors. Recently, the immunohistochemistry (IHC) markers S100B, SCGN, ACADL and MCM2 have been shown to be associated with underlying biological subtypes of meningioma (MG1-MG4). We aimed to evaluate these IHC markers in a clinical setting.
Are the new proposed IHC markers clinically useful?
In total, 244 patients with meningiomas with tissue in TMAs were included and the IHC markers S100B, SCGN, ACADL and MCM2 were analyzed. Two sets of analyses were performed; the first included all samples with any staining considered positive, the second only samples with >10% immunopositivity. PFS and OS were analyzed in correlation to immunopositivity in the second analysis set.
In the first set of analyses only 26.2% of samples could be to allocate to one group. No further analyses were performed with this selection. In the second set of analyses 52.0% could be allocated to a group. There was an enrichment of WHO grade 2 and 3 tumors in MG3 and MG4 as compared to MG1 (24.1% and 25.7% vs. 12.1%). Both the molecular group (p = 0.032) and WHO grade (p = 0.005) had significant impact on PFS, but only WHO grade predicted OS (p = 0.033).
We studied the proposed new method of classifying meningiomas into groups MG1, MG2, MG3 and MG4 using IHC markers, but found difficulties applying the classification system in our material mainly due to lack of exclusivity of markers. Thus, in its present form the classification method lacks clinical applicability.
脑膜瘤占颅内肿瘤的近40%。最近，免疫组化（IHC）标志物S100B、SCGN、ACADL和MCM2已被证明与脑膜瘤的潜在生物学亚型（MG1 - MG4）相关。我们旨在在临床环境中评估这些IHC标志物。
新提出的IHC标志物在临床上是否有用？
总共纳入了244例在组织微阵列（TMA）中有组织的脑膜瘤患者，并分析了IHC标志物S100B、SCGN、ACADL和MCM2。进行了两组分析；第一组包括所有任何染色被视为阳性的样本，第二组仅包括免疫阳性率>10%的样本。在第二组分析中，分析了无进展生存期（PFS）和总生存期（OS）与免疫阳性的相关性。
在第一组分析中，只有26.2%的样本可以分配到一个组。基于此选择未进行进一步分析。在第二组分析中，52.0%的样本可以分配到一个组。与MG1相比，MG3和MG4中WHO 2级和3级肿瘤有所富集（24.1%和25.7%对12.1%）。分子组（p = 0.032）和WHO分级（p = 0.005）对PFS均有显著影响，但只有WHO分级可预测OS（p = 0.033）。
我们研究了使用IHC标志物将脑膜瘤分为MG1、MG2、MG3和MG4组的新方法，但发现在我们的材料中应用该分类系统存在困难，主要原因是标志物缺乏排他性。因此，就目前形式而言，该分类方法缺乏临床适用性。
